

**Study Name :**  
New England Bladder Cancer Study

**Institutions:**  
National Cancer Institute Division of Cancer  
Epidemiology and Genetics (NCI-DCEG)  
Dartmouth Medical School  
New Hampshire Department of Health and Human  
Services  
Maine Department of Health and Human Services,  
Vermont Cancer Registry

**Principal Investigators:**

**NCI-DCEG:** Debra Silverman, Dalsu Baris

**Dartmouth Medical School:** Margaret Karagas, Richard  
Wadell

**Department of Health and Human Services, Maine  
Cancer Registry:** Molly Schwenn

**VT Cancer Registry:** Alison Johnson

**Key References:**

Baris D. et al. J Natl Cancer Inst. 2009 Nov 18;  
101(22):1553-61. Epub 2009 Nov 16.  
Colt JS, et al. Occup Environ Med. 2010 Sep 23.  
[Epub ahead of print]  
Moore L, et al. Carcinogenesis. 2010 Oct 29.  
[Epub ahead of print]

**Institution address:**

**NCI-DCEG:**  
6120 Executive Boulevard  
Bethesda, MD USA 20852-7234

**Dartmouth Medical School:**  
7927 Rubin Building, One Medical Center Drive,  
Lebanon, NH 03756

**Department of Health and Human Services, Maine  
Cancer Registry:**

Key Bank Plaza, 4th Floor  
Augusta, ME 04333

**VT Cancer Registry:**  
108 Cherry Street, Burlington, VT 05401

**Additional researchers:**

Angeline Andrew (Dartmouth Medical School)  
Bill Apao (Vermont)  
Laura Beane-Freeman (NCI)  
Ken Cantor (NCI, Lead Investigator)  
Sai Cherala (New Hampshire)  
Montserrat Garcia-Closas (NCI)  
Joanne Colt (NCI, Lead Investigator)  
Jay Lubin (NCI)  
Lee Moore (NCI)  
Nathaniel Rothman (NCI, Lead Investigator)  
Alan Schned (Dartmouth Medical School)  
Castine Verrill (Maine)

**Study Design:** Population based Case-Control  
**ICD-9 code:** 189.8  
**ICD-0-3 morphology codes:** 7400/6, 7400/7,  
8010/2, 8032/3, 8041/3, 8053/0, 8070/3, 8120/3,  
8130/3, 8140/3

**Matching factors:** age and sex  
**Follow up of cases?** Feasibility  
study is being initiated

**Country:** USA  
**Expected time of follow-  
up?**

Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303);  
Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)

|  | Cases  | Controls   |
|--|--|--|
| <b>Years of enrollment</b>               | 2001-2004  | 2001-2004  |
| <b>Source population</b>                 | Newly diagnosed<br>incident cases in<br>the states of New<br>Hampshire, Maine<br>and Vermont | Frequency<br>matched controls<br>selected from<br>Department of<br>Motor Vehicle (<65<br>years of age) and<br>Centers of<br>Medicare and<br>Medicaid Services<br>(>=65 years of age) |
| <b>Response rate (enrolled/eligible)</b> | 65%  | 65%  |
| <b>Total number enrolled</b>             | 1,213  | 1,418  |
| <b>Subjects with DNA</b>                 | 1,134  | 1,306  |
| <b>Ethnic origin</b>                     | 94% Caucasian  | 94% Caucasian  |
| <b>Age: mean (range)</b>                 | 65.16 (30-79)  | 64.52 (30-79)  |
| <b>Gender: % males</b>                   | 76% males  | 73%  |

| Questionnaire data  | Cases | Controls |
|---|-------|----------|
| Demographics (age, sex, ethnicity, region, education etc..) | x     | x        |

|                                   |   |   |
|-----------------------------------|---|---|
| Active smoking                    | X | X |
| Passive smoking                   | X | X |
| Occupational exposures            | X | X |
| Residential history               | X | X |
| Water chlorination byproducts     | X | X |
| Arsenic exposure                  | X | X |
| Other environmental exposures     | X | X |
| Hair dye use                      | X | X |
| Drug use                          | X | X |
| Medical History                   | X | X |
| Family History                    | X | X |
| Quality of life                   | - | - |
| Diet/nutrition                    | X | X |
| Caffeine intake                   | X | X |
| Fluid intake                      | X | X |
| Urine pH measurements             | X | X |
| Other information, please specify | - | - |

| Biological Samples                      | Cases | Controls |
|---|-------|----------|
| Blood DNA                               | X     | X        |
| Buccal DNA                              | X     | X        |
| Serum/plasma                            | X     | X        |
| Cryopreserved whole blood / lymphocytes | X     | X        |
| Red blood cells                         | X     | X        |
| Urine samples                           | X     | X        |
| Toenail clippings                       | X     | X        |
| Others, please specify                  | -     | -        |
| Paraffin tissue blocks                  | X     |          |
| Frozen tissue                           | -     |          |

#### For Cases Only

| Information at time of diagnosis   |   |
|------------------------------------|---|
| Histological confirmation          | X |
| Number of tumors                   | X |
| Tumor site                         | X |
| Tumor size                         | X |
| Tumor grade                        | X |
| Growth pattern                     | X |
| Treatment of primary tumor         | - |
| Stage                              | X |
| Other information, please specify  | - |
| Follow-up information              |   |
| Treatment information              | - |
| Tumor recurrence                   | - |
| Tumor progression                  | - |
| Survival                           | - |
| Histological confirmation          | - |
| Number of tumors                   | - |
| Tumor site                         | - |
| Tumor size                         | - |
| Tumor grade                        | - |
| Growth pattern                     | - |
| Stage                              | - |
| Active smoking                     | - |
| Occupational exposures             | - |
| Drug use                           | - |
| Medical History                    | - |
| Quality of life                    | - |
| Caffeine intake                    | - |
| Fluid intake                       | - |
| Other information , please specify | - |